OQROGet OQRO Pro
Insider trade

Xenon Pharmaceuticals (XENE)CEO sold ~$614K

Ian Mortimer, CEO at Xenon Pharmaceuticals, sold ~$614K of Xenon Pharmaceuticals shares.

~$614K
Approx. value · 15K sh @ $40.46
31K
Holds after · shares reported
Traded
Jan 27, 2025
Filed
Jan 28, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 18, 2024Insider · 1 personInsiders: 2 sales (~$771K)
  2. Jan 23, 2025InsiderCEO sold ~$650K of XENE shares in the open market
  3. Jan 24, 2025InsiderCEO sold ~$903K of XENE shares in the open market
  4. Jan 27, 2025 · this disclosureInsiderCEO sold ~$614K of XENE shares in the open market

What came next

  1. Jan 27, 2025InsiderCEO sold ~$47K of XENE shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Xenon Pharmaceuticals

For Xenon Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XENE page.

Other recent filings by Ian Mortimer, PRESIDENT & CEO

The full history of Ian Mortimer, PRESIDENT & CEO is on the profile page.

How this filing works

Other disclosures at Xenon Pharmaceuticals

Everything OQRO holds on this company is on its XENE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data